MedTrace Logo

A Study Of The Effect Of PF-04802540 On Sleep Measures

NCT00772512 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2010-03-19

No results posted yet for this study

Summary

The purpose of this study is to determine if PF-04802540 decreases REM sleep.

Conditions

  • Healthy

Interventions

DRUG

PF-04802540

5 mg capsule, single dose

DRUG

PF-04802540

15 mg capsule, single dose

DRUG

Placebo

Placebo capsule, single dose

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00772512 on ClinicalTrials.gov